Navigation Links
Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Date:2/27/2008

with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. AZ- 003 (Staccato fentanyl), which is partnered with Endo Pharmaceuticals in North America, for the treatment of breakthrough pain and AZ-007 (Staccato zaleplon) for the treatment of insomnia are in Phase 1 testing. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding growth of the Company's product candidate pipeline and development of the Company's product candidates. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2006, and the Company's other Periodic and Current Reports filed with the Securities and Exch
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
2. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
3. Pharmasset Appoints Michael Rogers as Chief Development Officer
4. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
5. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
6. Genstar Names Michael Hurt to Its Strategic Advisory Board
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
9. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
10. Royea Joins Eklin Medical Systems as VP of Worldwide Sales
11. Eric K. Rowinsky Joins ADVENTRX Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  Nektar Therapeutics (NASDAQ: NKTR ... the analgesic profiles of a series of the ... molecules. The preclinical research candidates were created using ... The analgesic properties of kappa receptor agonism ... Kappa opioid receptors are expressed in the ...
(Date:9/19/2014)... Florida , September 19, 2014 ... release latest developments, patents and results of studies and ... Eli Lilly and Company (NYSE: LLY ), ... Corporation (NASDAQ: CELG ) and Arena Pharmaceuticals ... a leader in developing prodrug therapeutics for the treatment ...
(Date:9/19/2014)... Minnesota (PRWEB) September 19, 2014 ... related food industries will gather October 5–8, 2014, ... the Rhode Island Convention Center in Providence, Rhode ... feature the work of food scientists, chemists, microbiologists, ... control, and food production management. To date, 1,000 ...
(Date:9/19/2014)... Massachusetts , September 19, 2014 ... the 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... of science and medical research in the field of ... Merck KGaA, Darmstadt, Germany , today ... Innovation (GGI) for 2014. The awards were announced during ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... , RESEARCH TRIANGLE PARK, N.C. , Feb. 4 ... company developing orally available antiviral therapeutics, announced today that ... as Chief Medical Officer.   , Dr. Painter has more ... work in clinical development, clinical safety and pharmacovigilance, and occupational ...
... ... at India World CEO Forum , ... New Delhi (Vocus) -- Industry has a unique opportunity today to engage, innovate and ... P. Vergnano at the World CEO Forum of the Delhi Sustainable Development Summit ...
... RICHMOND, Calif. , Feb. 3 Sangamo BioSciences, Inc. (Nasdaq: ... and accomplishments and provided an outlook for 2010. , For the fourth ... of $2.4 million , or $0.05 per share, compared to ... share, for the same period in 2008. As of December 31, 2009 ...
Cached Biology Technology:Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer 2Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer 3Sustainability Is A Business Imperative 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 7Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 8Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 9Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 10Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 11Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 12Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results 13
(Date:9/19/2014)... Nxt-ID, Inc. (Nasdaq: NXTD and NXTDW) ... growing m-commerce market, updates the "Wocket in Your Pocket" celebrity ad ... light middleweight weight classes, Vinny Pazienza (PAZ). ... Game of Thrones actor Ciaran Hinds and ... Katey Sagal have been cast in Bleed for ...
(Date:9/18/2014)... moon of Uranus, is one of the most visually ... its relatively small size, Miranda appears to have experienced ... formation of at least three remarkable and unique surface ... coronae are visible in Miranda,s southern hemisphere, and each ... the largest, has ridges and troughs with up to ...
(Date:9/18/2014)... matter how many times it,s demonstrated, it,s still ... , But by using a signaling system ... their behavior to suit their population. In short, ... present, and act accordingly. , Once the population ... change from innocuous to pathogenic, or from unhelpful ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... the scientific journal Zootaxa , researchers from Madagascar and ... The new bird was named Mentocrex beankaensis , ... and the new species beankaensis being coined after ... This species was distinguished from another in the same genus, ...
... by Edward Yu of Iowa State University and the Ames Laboratory ... pumps toxins from bacteria and allows them to resist antibiotics. ... journal Nature . The paper describes the co-crystal structure ... removes heavy metal toxins from bacteria. A research team led by ...
... compounds during the last year in search of potential new ... that one substance shows unusual promise. The early positive signs ... and cell cultures, they say in a report in ACS, ... colleagues, who include Nobel Laureate Stanley B. Prusiner, explain that ...
Cached Biology News:New bird to science emphasizes the critical need to conserve the remaining dry forests of Madagascar 2Iowa State, Ames Lab researchers describe the pump that bacteria use to resist drugs 2
Human Norrin Biotinylated Affinity Purified PAb Protein Family: Other Growth Factors, Other Wnt-related Molecules...
Human VASA Biotinylated Affinity Purified PAb...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
interferon-related developmental regulator 2...
Biology Products: